Genentech licenses Hanmi obesity candidate in deal worth up to $2.3 billion

Genentech has licensed an obesity drug candidate from Hanmi Pharmaceutical in a deal worth up to $2.3 billion, the latest sign that large drugmakers are willing to pay for weight-loss treatments that do not work through the same GLP-1 pathway as the medicines now on the market ^[1].

The candidate is based on UCN2, which makes it a non-GLP-1 mechanism ^[1]. That separates it from semaglutide, the molecule in Novo Nordisk's Ozempic, Wegovy and Rybelsus, and from the GLP-1 drugs that have dominated US weight-management sales.

The deal's structure has not been disclosed. Genentech and Hanmi have not reported the upfront payment, the size or timing of the milestone payments that would make up the rest of the $2.3 billion total, or which countries the license covers. Whether the agreement includes royalties on future sales also has not been reported.

The same is true of the science. The stage of clinical testing for the Hanmi candidate has not been disclosed, and no results from human trials have been reported. Licensing deals are often signed years before a drug reaches patients, and most candidates that enter such deals never win approval.

The agreement lands in a market that is moving quickly. Novo Nordisk launched an oral version of Wegovy, its semaglutide-based weight-loss drug, in the US in early January 2026, making it the first oral GLP-1 receptor agonist available in the country for weight management ^[1]. Eli Lilly's rival oral candidate, orforglipron, is still under regulatory review ^[1]. Novo Nordisk's launch was seen as a chance to define the oral market before that review finishes ^[1].

Why it matters for patients

Nothing about the Genentech–Hanmi deal changes what is available today. No prescription, dose or coverage decision is affected by a licensing agreement for a drug that has not been shown to work in people.

What the deal signals is money moving toward mechanisms other than GLP-1. Semaglutide and tirzepatide are effective for many people but not all, and some patients stop taking them because of side effects. Additional mechanisms could eventually offer options for people who do not respond well to, or cannot tolerate, the current drugs. That possibility depends on clinical results that have not been reported for this candidate.

Pricing and insurance coverage for any future non-GLP-1 obesity drug are also unknown. No company has disclosed what a UCN2-based treatment would cost or whether insurers would cover it.

What happens next

No trial start, data readout or approval date for the Hanmi candidate has been disclosed. The nearest dated marker in the oral obesity market is Lilly's orforglipron, which remains under regulatory review ^[1]; a decision date has not been reported here.

For now, the deal is a financial commitment rather than a clinical one. Investors and patients will learn whether the UCN2 approach works only when human trial data are released, and no timeline for that release has been made public.